Related Experiment Video
Updated: Jan 29, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
NRF2 Activation in Cancer: From DNA to Protein
Erica W Cloer1,2, Dennis Goldfarb2,3, Travis P Schrank2,4
1Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.
Abstract:
The Cancer Genome Atlas catalogued alterations in the Kelch-like ECH-associated protein 1 and nuclear factor erythroid 2-related factor 2 (NRF2) signaling pathway in 6.3% of patient samples across 226 studies, with significant enrichment in lung and upper airway cancers. These alterations constitutively activate NRF2-dependent gene transcription to promote many of the cancer hallmarks, including cellular resistance to oxidative stress, xenobiotic efflux, proliferation, and metabolic reprogramming. Almost universally, NRF2 activity strongly associates with poor patient prognosis and chemo- and radioresistance. Yet to date, FDA-approved drugs targeting NRF2 activity in cancer have not been realized. Here, we review various mechanisms that contribute to NRF2 activation in cancer, organized around the central dogma of molecular biology (i) at the DNA level with genomic and epigenetic alterations, (ii) at the RNA level including differential mRNA splicing and stability, and (iii) at the protein level comprising altered posttranslational modifications and protein-protein interactions. Ultimately, defining and understanding the mechanisms responsible for NRF2 activation in cancer may lead to novel targets for therapeutic intervention.
Insights
Alterations in the NRF2 pathway are common in lung cancers, promoting tumor growth and resistance to treatment. Understanding these changes could lead to new cancer therapies targeting NRF2 activity.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- The Kelch-like ECH-associated protein 1 and nuclear factor erythroid 2-related factor 2 (NRF2) signaling pathway is frequently altered in cancer.
- These alterations are enriched in lung and upper airway cancers, affecting 6.3% of patient samples across 226 studies.
- Constitutive NRF2 activation drives cancer hallmarks like oxidative stress resistance, proliferation, and metabolic reprogramming, correlating with poor prognosis and treatment resistance.
Purpose of the Study:
- To review the diverse mechanisms underlying NRF2 activation in cancer.
- To organize these mechanisms according to the central dogma of molecular biology: DNA, RNA, and protein levels.
- To highlight the potential for novel therapeutic targets based on a comprehensive understanding of NRF2 activation.
Main Methods:
- Literature review of The Cancer Genome Atlas (TCGA) data.
- Analysis of genomic, epigenetic, mRNA splicing, mRNA stability, posttranslational modifications, and protein-protein interaction data.
- Categorization of NRF2 activation mechanisms by molecular level (DNA, RNA, protein).
Main Results:
- NRF2 pathway alterations are prevalent in various cancers, particularly lung and upper airway types.
- Activated NRF2 signaling promotes key cancer-promoting processes and is linked to adverse patient outcomes.
- Mechanisms of NRF2 activation span DNA alterations, RNA processing, and protein modifications.
Conclusions:
- NRF2 activation is a critical oncogenic mechanism with diverse regulatory pathways.
- A thorough understanding of these mechanisms is essential for developing targeted NRF2-based cancer therapies.
- Despite its prevalence and impact, effective FDA-approved drugs targeting NRF2 in cancer are still lacking.
Related Concept Videos
From DNA to Protein
Activation and Inactivation of G Proteins
DNA Helicases
Single-Strand DNA Binding Proteins
Co-activators and Co-repressors
DNA Packaging

